Display Settings:

Format

Send to:

Choose Destination

Glutamate-related biomarkers in drug development for disorders of the nervous system : workshop summary

Author(s):
Pankevich, Diana E, 1975-
Altevogt, Bruce M
Davis, Miriam, (Medical writer)
Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders
Title(s):
Glutamate-related biomarkers in drug development for disorders of the nervous system : workshop summary / Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
Country of Publication:
United States
Publisher:
Washington, D.C. : National Academies Press, c2011.
Description:
xii, 61 p. : ill. (some col.) ; 23 cm.
Language:
English
ISBN:
9780309212212
0309212219
Electronic Links:
http://www.ncbi.nlm.nih.gov/books/NBK62179/
http://www.nap.edu/catalog.php?record_id=13146
Summary:
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
MeSH:
Biological Markers, Pharmacological*
Central Nervous System Diseases/diagnosis*
Central Nervous System/drug effects
Drug Discovery
Glutamic Acid/adverse effects
Neuropharmacology/methods
Publication Type(s):
Congresses
Notes:
Includes bibliographical references.
Also available online.
NLM ID:
101571253 [Book]

Supplemental Content

Loading ...
Write to the Help Desk